{"slideshow_credits": null, "snippet": "Valeant, which has grown by acquiring rivals and slashing their staffs, has drawn the ire of a House panel, which is now considering a subpoena on the company\u2019s price increases.", "abstract": "Gretchen Morgenson Fair Game column observes that investors in drug companies are starting to see the danger in firms like Valeant Pharmaceuticals raising prices indiscriminately to increase stock prices; points out House panel may issue subpoena against Valeant. ", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Gretchen", "role": "reported", "lastname": "MORGENSON", "rank": 1, "organization": ""}], "original": "By GRETCHEN MORGENSON"}, "web_url": "http://www.nytimes.com/2015/10/04/business/valeants-high-price-drug-strategy.html", "lead_paragraph": "Valeant, which has grown by acquiring rivals and slashing their staffs, has drawn the ire of a House panel, which is now considering a subpoena on the company\u2019s price increases.", "headline": {"print_headline": "Side Effects of Hijacking Drug Prices", "main": "Valeant\u2019s High-Price Drug Strategy", "content_kicker": "Fair Game", "kicker": "Fair Game"}, "_id": "560ea61638f0d81aa77a547d", "word_count": "1070", "multimedia": [{"height": 126, "url": "images/2015/10/04/business/04gret-web1/04gret-web1-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/10/04/business/04gret-web1/04gret-web1-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 413, "url": "images/2015/10/04/business/04gret-web1/04gret-web1-articleLarge.jpg", "legacy": {"xlarge": "images/2015/10/04/business/04gret-web1/04gret-web1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "413"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/10/04/business/04gret-web1/04gret-web1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/10/04/business/04gret-web1/04gret-web1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-10-04T00:00:00Z", "source": "The New York Times", "news_desk": "SundayBusiness", "keywords": [{"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Stocks and Bonds", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "4"}, {"name": "persons", "value": "Cummings, Elijah", "is_major": "N", "rank": "5"}, {"name": "organizations", "value": "House Committee on Oversight and Government Reform", "is_major": "N", "rank": "6"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "7"}, {"name": "subject", "value": "Corporate Taxes", "is_major": "N", "rank": "8"}, {"name": "persons", "value": "Pearson, John Michael (1959- )", "is_major": "N", "rank": "9"}], "blog": [], "subsection_name": null, "type_of_material": "News"}